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ABSTRACT 
AN EXPLORATORY STUDY OF THE UTILIZATION OF EVIDENCE-BASED 
PHARMACOLOGICAL TREATMENT ON HEART FAILURE PATIENTS IN 
MISSISSIPPI AND ITS IMPACT ON READMISSION 
by Keri Annalyn Barron  
May 2017 
The purpose of this study was to explore the relationship of adherence to 
evidence-based guidelines for pharmacologic management by select Mississippi hospitals 
and their hospital readmission rates.  This was an exploratory study with a retrospective 
design.  This design offered insight into the relationship between readmissions of heart 
failure patients and adherence to the national guidelines for the pharmacologic treatment 
of heart failure.  The study took place in a hospital in the southeastern section of the 
United States.  Data were collected from a database of patients with heart failure seen 
between January 2011 and June 2014.   
The unit of analysis for this study was the hospitalizations of the heart failure 
patients.  The researcher limited the study to the first 30 days of the patient’s index 
hospitalization and readmissions included in that period.  Patient inclusion criteria for this 
study included: 18 years of age and older with a diagnosis of heart failure as identified by 
the International Classification of Disease (ICD – 9) Codes for heart failure.  A 
researcher generated data abstraction tool was used to collect data on the variables of 
interest: demographic variables and clinical variables.  A total of 31 charts comprised the 
sample.  The Statistical Package for the Social Science (SPSS) software version 23 was 
used to analyze collected data.   
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The overall findings of this study indicated that patients frequently readmit to the 
hospital within 30 days of discharge; however, a relationship was not seen between 
evidence-based pharmacological therapy and readmission.  The researcher concluded that 
this finding was due to the small amount of data for analysis.  The results also revealed 
that some of the pharmacological classes of medications were not utilized, or insufficient 
documentation existed about their use or lack thereof. 
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CHAPTER I – STATEMENT OF THE PROBLEM 
Heart failure is a disease often associated with undesirable outcomes: a decrease 
in health and death.  A national health care issue, this disease affects myriad individuals 
whose treatment costs often prove staggeringly high (Centers for Disease Control and 
Prevention, 2013).  During onset of heart failure, the heart loses its capability to supply 
the body with an adequate blood supply.  As a result, patients lose their ability to engage 
in daily functions (American Heart Association, 2015a).  By the year 2030, heart failure 
will cost the United States an estimated $77.7 billion dollars in direct medical costs 
(Heidenreich et al., 2011, p. 935).  Hospital costs related to this disease’s management 
contribute to a major portion of overall hospital expenses (O’Connell, 2000, p. III-7).  A 
heart failure hospitalization can cost as much as $25,000 and can rise by hundreds of 
dollars with each intervention utilized, such as nursing, pharmacotherapy, and/or medical 
procedures (Titler et al., 2008; Wang, Zhang, Ayala, Wall, & Fang, 2010).   
The lifetime costs associated with the disease are extreme as well.  Heart failure 
patients can incur lifetime management costs up to approximately $118,000.  Most of 
these costs are incurred during patients’ hospital stays.  Indeed, hospital costs can reach 
approximately $84,000 per patient (Dunlay et al., 2011, p. 68).  The average cost of stay 
for a heart failure patient readmitted within 30 days of discharge is $13,000 (Qasim & 
Andrews, 2012, p. 3).  For this reason, the Center for Medicare and other agencies have 
instituted policies to restrict payment to healthcare institutions (Medicare.gov, n.d.).   
While many evidence-based strategies explore ways to reduce these readmissions, 
healthcare facilities disagree about the strategies used to reduce readmissions.  Shan, 
Finder, Dichoso, and Lewis (2014) reported that even though there are interventions 
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favorable to the reduction of heart failure readmissions, such as the transition of care, 
managing medications, discharge planning, and follow-up care, hospitals still have issues 
with implementation of interventions or an absence of interventions altogether.  As a 
result, heart failure readmissions remain unacceptably high.  Hospitals must be able to 
implement these interventions to reduce heart failure readmissions.   
Heart failure affects individuals across all ethnic/racial and age groups.  The 
numbers of individuals affected by heart failure are in the high millions (National Heart, 
Lung, and Blood Institute, 2012, p. 5).  African Americans are at the top of the list for the 
incidence of heart failure.  Hispanics and Caucasians are next, followed by Chinese 
Americans (Bahrami et al., 2008, pp. 5-6).  Caucasian males are at an increased risk of 
developing heart failure relative to African American males due to health-related factors, 
such as obesity, high blood pressure, and heart attack (Huffman et al., 2013, p. 1510).  
Although Caucasian males experience an increased risk of developing the disease, 
African-American males over age 60 suffer increased incidence.  This is in part due to 
African American males suffering greater risk factors that affect the heart’s blood 
vessels, such as hypertension and diabetes (Loehr, Rosamond, Chang, Folsom, & 
Chambless, 2008, p. 1019).   
In Mississippi, heart failure is a particularly significant issue.  While chronic 
disease accounted for 41.2% of hospital discharges in Mississippi in 2010, heart failure 
was the most prevalent of the top three chronic diseases cited for discharges.  The other 
two chronic diseases were chronic obstructive pulmonary disease and diabetes mellitus.  
These discharges accounted for approximately $289,000,000 in hospital charges (Short, 
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2014, p. 9).  Vital records between 1999-2010 revealed Jackson, Mississippi, to have the 
most heart failure-related deaths (Snyder et al., 2014, p. 5). 
Heart Failure Readmissions 
Readmissions of discharged patients affect all healthcare institutions in the United 
States, as readmissions consistently increase healthcare costs.  The Centers for Medicare 
and Medicaid Services (CMS) (2014) defines readmissions as “an admission to a 
subsection (d) hospital within 30 days of discharge from the same or another subsection 
(d) hospital.”  Subsection (d) hospitals are Medicare hospitals that receive payment from 
the Inpatient Prospective Payment System (IPPS), a system that pays based on a patient’s 
diagnosis-related group (DRG) (Centers for Medicare and Medicaid Services, 2016a, 
2016b).  Despite penalties imposed by CMS, patient readmissions during unacceptable 
time periods have not significantly abated in all states.  Indeed, Mississippi’s 
readmissions remain at unacceptable levels.  
CMS monitors the number of readmissions to healthcare institutions yearly across 
the U.S. and has determined the national readmission rate for heart failure to be 22% 
(Data.medicare.gov, 2015a).  In 2011, congestive heart failure was cited as the principal 
diagnosis for patient readmissions in the United States.  Congestive heart failure 
accounted for 134,500 patients’ readmissions within 30 days of their initial hospital 
release.  Those repeat visits resulted in $1.7 billion dollars in healthcare costs (Hines, 
Barrett, Jiang, & Steiner, 2014, p. 3).  
While data exist that explicate Mississippi readmissions data, inclusive of hospital 
guidelines to reduce heart failure readmissions, comparative data are not available that 
inform about how Mississippi hospital medication guidelines compare with national 
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evidence-based practice educational guidelines for reducing heart failure readmissions.  
Evidence-based practice is the application of best available researched evidence into 
practice (Grimmer, Bialocerkowski, Kumar, & Milanese, 2004, p. 189).  Evidence-based 
practice guidelines are recommendations supported by research that guide clinicians 
during patient care (Graham, Mancher, & Wolman, 2011).  McKenna, Ashton, and 
Keeney (2004) reported that evidence helps to provide quality health service; however, 
barriers prevent the best evidence’s translation to practice.  Some of these barriers include 
little relevance to utilize research into practice, lack of a facilitator to influence change 
and having already to remain aware of current changes in healthcare (p. 186-188).   
Several clinical practice guidelines assist in the care of patients with heart failure: 
(a) the 2013 American College of Cardiology Foundation/American Heart Association 
Guideline for the Management of Heart Failure (ACCF/AHA), (b) the Heart Failure 
Society of American Heart Failure Guidelines, and (c) American Heart Association Get 
with the Guidelines-Heart Failure (AHA, 2015b; Lidenfeld et al., 2010; Yancy et al., 
2013).  The ACCF/AHA guidelines prove the most commonly used out of the three.  No 
previous studies have compared guidelines for treating heart failure with practices used 
by health care professionals for treating heart failure in Mississippi.  Also, there is a lack 
of comparative data to determine whether a relationship exists between evidence-based 
pharmacological treatment and readmissions of patients with heart failure in Mississippi.   
Purpose of the Study 
The purpose of this study was to explore the relationship of adherence to 
evidence-based guidelines for pharmacologic management by select Mississippi hospitals 
and their hospital readmission rates, particularly as these factors relate to heart failure. 
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Research Questions 
This study’s research sought to determine the relationship between adherence to 
pharmacological clinical practice guidelines for heart failure patients and readmissions to 
select Mississippi hospitals within 30 days or fewer after discharge.  
The following questions guided this study: 
1. To what extent are select Mississippi hospitals adhering to evidence-based 
pharmacological management guidelines for management of heart failure? 
2. What is the relationship between adherence to guidelines for pharmacologic 
management of heart failure and readmission in Mississippi hospitals? 
Theoretical Framework 
The care of heart failure patients and reduction of readmissions requires an 
ongoing relationship between the healthcare system, healthcare system providers, and 
patients who are supported by evidence-based practice.  Wagner’s Chronic Care Model 
(Wagner, Austin, & Korff, 1996) and the theoretical concepts of Donabedian’s Quality of 
Care Framework (Donabedian, Wheeler, & Wyszewianski, 1982) combined to form this 
study’s theoretical framework. 
The Chronic Care Model is composed of six components that intend to address 
inconsistencies that sometimes occur in management of patients with chronic disease.  
These components focus on the care received within the hospital, as well care provided in 
the community.  First, the model examines the healthcare organization and structures 
within the organization that impact care provided to chronically ill patients. Inclusive are 
the systems used to monitor the care of the patients, the mechanisms physicians use to 
guide treatment, and the care the patients receive. Secondly, the model incorporates 
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resources in the community that would encourage self-management (Wagner et al., 2002, 
p. 70).   
Wagner et al. (1996) conducted a meta-analysis to examine the common 
characteristics among programs, randomized controlled studies, and interventions in 
other countries that were successful in the management of chronic illness.  Wagner et al. 
(1996) determined that those programs, studies, and interventions were successful 
because they shared common several key factors. They followed plans and protocols, met 
the needs of the patients through follow-ups, resources, and the provision of more time if 
patients needed it, paid attention to changes in their patients, provided experts available 
when needed, and offered necessary information systems (p. 518).   
The ACCF and AHA have determined through evidence-based research that their 
heart failure guidelines can influence the health status of heart failure patients.  The 
researcher submits that Wagner’s Chronic Care Model appropriately undergirds this 
proposed study based upon the six constructs of the model. These constructs provide a 
means for understanding evidence-based guidelines in treating heart failure.  Stated 
differently, this study encompasses the importance of following plans and protocols as 
well as paying attention to patients, promoted via Wagner’s research and the use of 
evidence-based research in practice.  The utilization of Wagner’s model in the redesign of 
healthcare protocols has the potential to lead to lower costs and better well-being for 
chronically ill individuals (Coleman, Austin, Brach, & Wagner, 2009).   
Donabedian et al. (1982) described a framework that illustrates the importance of 
a relationship between the health of the patient, quality of care provided, and the costs 
associated with that care.  This framework further defines quality care as being the care 
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that yields the greatest expected improvement in the patient’s health physically, 
physiologically, and psychologically (p. 976).  As such, Donabedian et al.’s (1982) 
framework fits the present study because quality care for heart failure patients must 
incorporate the health of the patient, cost-effective treatments, and quality care.  To 
provide quality care, the researcher submits that healthcare institutions must incorporate 
evidence-based practice measures into patient care.   
Donabedian et al.’s (1982) framework is composed of three parts: structure, 
process, and outcomes. Structure refers to the setting in which the patient receives care.  
The process is the actual care that the patient receives, and the outcome is the result of the 
patient’s health status after receiving care (Schroeder et al., 2006).  The utilization of 
outcome as a measure of quality is an accepted measure in many cultures.  Improved 
health is always a welcomed outcome, and the outcomes become more consistently valid 
because they can be measured repeatedly.  Thus outcomes can continually validate 
whether healthcare measures are effective (Donabedian, 2005, pp. 693-694).  Donabedian 
et al.’s (1982) framework fits this study because its constructs guides the researcher’s 
understanding of outcomes and how to use readmission outcomes as a means to measure 
evidence-based heart failure guidelines in practice. 
Definition of Terms 
Theoretical Definitions 
The following terms were utilized in this project: 
1. Heart Failure: is the heart’s inability to pump oxygen-rich blood (Chen, 2014).  
Heart failure is a serious condition that affects the left/right or both sides of 
the heart.  Right-sided heart failure interferes with the heart’s ability to 
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adequately profuse the lungs with oxygen.  Left-sided heart failure interferes 
with the lungs’ ability to adequately profuse the body with oxygen (National 
Heart, Lung, and Blood Institute [NHLBI], 2014). 
2. Evidence-based practice: the incorporation of research supported by evidence, 
practice, and patients’ perspectives to improve clinical decisions for patients 
(Agency for Healthcare Research and Quality [AHRQ], n.d.). Research 
methods conducted by nurses, clinicians, and other healthcare disciplines, 
including quasi-experimental designs, descriptive research, qualitative 
research, randomized controlled trials, and expert opinion are employed for 
clinical practice (Puddy & Wilkins, 2011; Titler, 2008).  The integration of all 
these components into clinical decision-making enhances opportunities for 
patients to receive better quality of life and clinical outcomes (“Introduction to 
Evidence-Based Practice,” n.d.). 
3. Hospital readmission: a repeat admission to a hospital before being out of the 
hospital for 30 days (Centers for Medicare and Medicaid Services [CMS], 
2014). 
4. National guidelines for treating heart failure: evidence-based guidelines that guide 
healthcare providers in their decisions about managing heart failure 
(Lidenfield et al., 2010; Yancy et al., 2013).  
Operational Definitions 
For the purposes of this study the following operational definitions were 
employed: 
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1. Heart Failure: the primary diagnosis associated with patients’ readmissions.  A 
diagnosis of heart failure will be identified using the patients’ admission 
diagnosis and/or an ICD-9 code as displayed in Table 1.   
2. Readmission: For this study, readmissions were defined as a subsequent hospital 
admission within 30 days of, discharge as identified by the healthcare 
institution’s medical records database. 
3. Pharmacological guidelines for treating heart failure: The ACCF/AHA guidelines 
for pharmacological management of heart failure are listed in Table 2. 
Table 1  
ICD – 9 Codes for Heart Failure 
ICD-9 CODE ICD-9 CODE DESCRIPTION 
 
428.0 
 
CONGESTIVE HEART FAILURE UNSPECIFIED 
 
428.1 LEFT HEART FAILURE 
 
428.20 UNSPECIFIED SYSTOLIC HEART FAILURE 
 
428.21 ACUTE SYSTOLIC HEART FAILURE 
 
428.22 CHRONIC SYSTOLIC HEART FAILURE 
 
428.23 ACUTE ON CHRONIC SYSTOLIC HEART FAILURE 
 
428.30 UNSPECIFIED DIASTOLIC HEART FAILURE 
 
428.31 ACUTE DIASTOLIC HEART FAILURE 
 
428.32 CHRONIC DIASTOLIC HEART FAILURE 
 
428.33 ACUTE ON CHRONIC DIASTOLIC HEART FAILURE 
 
428.40 UNSPECIFIED COMBINED SYSTOLIC AND DIASTOLIC HEART 
FAILURE 
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428.41 ACUTE COMBINED SYSTOLIC AND DIASTOLIC HEART 
FAILURE 
 
428.42 CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART 
FAILURE 
 
428.43 ACUTE ON CHRONIC COMBINED SYSTOLIC AND DIASTOLIC 
HEART FAILURE 
 
428.9 HEART FAILURE UNSPECIFIED  
Adapted from Centers for Medicare and Medicaid Services, n.d. 
Table 2  
Stages of Heart Failure 
Stage Pharmacological Guideline 
 
STAGE A 
- at risk for heart 
failure 
- has conditions 
such as high blood 
pressure or 
diabetes 
 
1.  Treatment with an angiotensin-converting enzyme inhibitors 
(ACEI) or angiotensin receptor blockers (ARB), as appropriate, to 
control the conditions that might contribute to heart failure. 
2.  Treatment with statins, as appropriate, in these patients as well. 
 
STAGE B 
- at risk for heart 
failure due to heart 
disease 
- no signs and 
symptoms of heart 
failure present   
 
1.  An ACEI or ARB is recommended, as appropriate, to prevent 
heart failure 
2.  Beta-blockers (BB) are recommended, as appropriate, to prevent 
heart failure. 
3.  Statins are recommended, as appropriate, in patients with a 
history of heart attack to prevent heart failure.   
4.  ACEIs and BBs are recommended, as appropriate, with an 
ejection fraction (EF) < 35% to prevent heart failure   
 
STAGE C 
- heart disease 
present 
- has signs and 
symptoms of heart 
failure presently or 
in the past  
 
Reduced EF 
1. An ACEI, ARB, or BBs recommended if appropriate.  
2.  Diuretics are recommended, as appropriate, to relieve fluid 
retention. 
3.  Aldosterone antagonists (AA) are recommended, as appropriate, 
to reduce effects of the disease and the occurrence of death.  
4.  Hydralazine and Isosorbide Dinitrates are recommended, as 
appropriate, if the patient cannot tolerate an ACEI or an ARB.   
5.  Digoxin is recommended, as appropriate, to decrease 
hospitalization. 
 Preserved EF 
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1. ACEIs, ARBs, and BB can be used, as appropriate, to control 
blood pressure. 
2.  Diuretics are recommended, as appropriate, to relieve symptoms 
of volume overload. 
3.  AAs may also be used, as appropriate, in heart failure patients to 
decrease their chance of hospitalization. 
 
 
STAGE D 
- advanced heart 
failure or end-
stage heart failure  
- heart failure 
symptoms occur at 
rest  
 
Advanced pharmacological treatment, such as inotropic agents, is 
recommended for patients in this category.   
 Adapted from Yancy et al., 2013, p. e284. 
Assumptions 
The following assumptions applied to this study: 
1. Evidence-based guidelines are adhered to in healthcare institutions, especially 
hospitals. 
2. Documentation would be sufficient throughout the patients’ medical records thus 
increasing the probability of sufficient information to be collected and 
analyzed for this study. 
Limitations, Scope, and Delimitations 
The primary limitation of this study was the small sample size.  The researcher 
was only able to examine a total of 31 charts, due to chart availability and the limited 
number of staff available to pull more charts.  The results of the study did indicate a 
possibility of a relationship among the variables if more data were available for analysis.  
A further limitation of the study was the lack of generalizability beyond the patients 
included in the sample.  This was due to small sample size and the limitation of one 
setting for data collection.  The findings from the study were expected to increase 
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awareness on the importance of utilizing evidence-based research in the management of 
heart failure, as well as other diseases.  The findings were also expected to illustrate the 
importance of sufficient documentation in the patients’ medical records due to the 
identification of insufficient documentation while conducting data collection. 
Significance of the Study 
There is an unfortunate paucity of literature that compares practice patterns at 
Mississippi hospitals with national evidence-based guidelines for treating heart failure.  
As mentioned, the prevalence of heart failure in Mississippi is significant.  Heart failure 
has been cited as one of the most prevalent discharge diagnoses in Mississippi, and one of 
the primary causes of death in Mississippi patients.  There are data that explicate 
Mississippi readmissions data; however, there are not data available to compare 
guidelines Mississippi hospitals use to reduce admissions with those of national 
evidence-based practice guidelines. 
Findings from the study aspires to offer additional knowledge about gaps in the 
implementation of clinical practice guidelines in the management of Mississippi patients 
with heart failure.  Further, the study contributes rudimentary data for future research that 
might inform best pharmacological practices for reducing readmissions among those 
patients.  Finally, the findings of this study informs healthcare practices and possible 
changes amenable to health policies.   
Summary 
Chapter I introduced a serious healthcare problem the nation, and particularly 
Mississippi, faces heart failure. Chapter I also introduced the impact readmissions have 
on the healthcare system.  This chapter provided the initial foundation for this study by 
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describing the purpose of this study, the research questions used to guide the study, and 
the theoretical framework used to support the study.  The theoretical and operational 
definitions utilized throughout this study were defined.  A description of the assumptions, 
limitations, and scope were also provided, as well as a description of the study’s 
significance.  Chapter II reviews the literature related to the utilization of evidence-based 
guidelines and readmissions. 
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CHAPTER II – REVIEW OF LITERATURE 
Introduction 
This literature review consisted of research related to evidence-based guidelines 
for the treatment of heart failure, studies related to the utilization of those guidelines, and 
studies related to heart failure readmissions.  Databases and search engines accessed for 
this literature review included Medline, EBSCOhost, ScienceDirect, Dissertation and 
Theses, and CINAHL with full text.  Research findings were limited to those written in 
English.  Keywords searched included: evidence-based guidelines, heart failure, 
evidence-based therapies, angiotensin-converting enzymes inhibitors, angiotensin-
receptor blockers, aldosterone antagonists, beta blockers, readmissions, and Mississippi.  
American College of Cardiology Foundation/American Heart Association Heart Failure 
Guidelines 
The ACCF/AHA developed a comprehensive set of guidelines to assist health 
care professionals to manage heart failure patients, which the literature divides into eight 
sections.  Sections one and two introduce the guidelines and define heart failure, 
respectively.  Section three examines the four classifications of heart failure, and section 
four explores the epidemiology of the disease.  Section five discusses the causes of heart 
failure, divided into cardiac structural abnormalities and other causes.  Section six 
provides recommendations for the patient’s initial evaluation as well as the serial 
evaluations that will follow.  Section seven presents the recommended treatment for the 
disease based on each progressive stage of heart failure.  The final section, section eight, 
describes how to care for a heart failure patient during hospitalization (Yancy et al., 2013, 
pp. e241-e242).   
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For the purpose of this study, the researcher explored the pharmacological 
treatment recommendations for heart failure.  The well-being and ability to perform day 
to day activities of those affected with heart failure are predictors of hospital 
readmissions (Moser et al., 2009, p. 766).  Both the symptoms and management of those 
symptoms influence the heart failure patient’s well-being and ability to function.  The 
care provided embodies the utilization of appropriate treatment for symptoms related to 
the disease (Ekman et al., 2005, p. 292). 
Four primary pharmacological classes are recognized in the ACCF/AHA 
guidelines for treating heart failure: angiotensin-converting enzymes (ACEIs) inhibitors, 
angiotensin-receptor blockers (ARBs), aldosterone antagonists (Aas), and beta blockers 
(BBs).  Diuretics, digoxin, and other medications are recommended in patients with 
advanced disease.  There are recommendations that these medications be increased in 
small doses to achieve optimal guideline-directed medical therapy (Yancy et al., 2013, p. 
e276). 
Angiotensin-Converting Enzyme Inhibitors   
ACEIs block the body’s production of angiotensin II, which constricts blood 
vessels.  In patients with hypertension, ace inhibitors keep those vessels open because 
hypertension is a precursor for heart failure. These medications are especially important 
because they decrease the work requirement in the already weakened heart muscle 
(Sweitzer, 2003, p. e16).  The utilization of these medications has been associated with 
reduced mortality, hospitalizations, and repeat hospitalizations.  The ACCF recommend 
ACEIs in all patients affected by heart disease in an attempt to prevent heart failure.  The 
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organizations also recommend these medications to prevent symptoms heart failure 
patients might exhibit (Yancy et al., 2013, p. e261).   
Fu et al. (2012) analyzed seven prospective studies to evaluate their prognostic 
effect on chronic heart failure patients with a preserved EF versus other medications.  
Researchers found both death due to all-cause and repeat hospitalizations were reduced 
with the utilization of these medications.  They discovered that the majority of the cases 
were due to hypertension (69%).  This was followed by 33.7% of the cases catalyzed by 
ischemic heart disease and 25.8% of the cases owed to diabetes mellitus.  
 Sanam et al. (2014) also explored the association between ACEIs and 
readmissions by examining the prescriptions of patients with heart failure before 
discharge.  Similar results were found in that there was a reduction readmissions and 
mortality.  Shah et al. (2013) contributed to these findings via their study of the effects 
ACEIs, along with beta blockers, had on patient outcomes.  They performed a repeat 
analysis of the Biomarkers in Acute Heart Failure (BACH) trial, an international 
prospective study that investigated the presentation of heart failure patients to the 
emergency room exhibiting shortness of breath (Maisel et al., 2010).  It was found that 
patients had an increased chance of survival if discharged on both medications, with the 
ace inhibitor serving as the survival agent.   
Angiotensin-Receptor Blockers 
 ARBs are similar to ace inhibitors in that they also regulate the angiotensin II 
hormone.  These medications inhibit the effect of the hormone, thus lessening the adverse 
effects associated with ace inhibitors (Barreras & Gurk-Turner, 2003, p. 123; Terra, 
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2003).  ARBs are recommended in patients affected by heart disease in an attempt to 
prevent heart failure and its associated symptoms (Yancy et al., 2013, p. e261). 
There are varying reviews of the utilization of the above-mentioned medications.  
According to previous studies, ARBs are beneficial to heart failure patients when used 
concurrently with ace inhibitors.  There have been limited associations between the sole 
use of the medications in the reduction of death and repeated admissions to the hospital; 
however, there are studies that suggest they might benefit patients who are intolerant to 
ace inhibitors.   
Dickstein (2001) reviewed two trial studies, the Elderly Losartan Heart Failure 
Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT), to examine 
the effect ARBs had on prevalence of the disease and death.  Losartan, an ARB, was 
compared to captopril, an ACEI, in the ELITE II trial.  The Val-HeFT trial investigated 
valsartan, an ARB, against a placebo.  In both trials, the target dose of medication was 
achieved by more than 75% of the patients.  Patients tolerated ARBs in both trials; 
however, a difference was not seen in death when comparing losartan and captopril in the 
ELITE II trial.  The author did report, however, that patients taking valsartan as opposed 
to the placebo in the Val-HeFT trial did experience a reduction in hospitalization and 
death or disease (p. 241). 
McMurray (2001) added to this by also reviewing the Val-HeFT and ELITE II 
trials along with the Candesartan in Heart Failure: Assessment of Reduction in Mortality 
and Morbidity (CHARM), and the Irbesartan in Patients with Heart Failure and Preserved 
Ejection Fraction (I-PRESERVE) trial.  The same findings were reported as Dickstein 
(2001) in that the patients in the Val-HeFT and ELITE II tolerated ARB treatment.  
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Additionally, patients on an ARB in the Val-HeFT trial had a reduction in 
hospitalizations as compared to those taking a placebo.  The CHARM and I-PRESERVE 
trials are still in their developmental stages but will compare the utilization of an ARB to 
a placebo.  Researchers did report that participants in the Study of Patients Intolerant of 
Converting Enzyme Inhibitors (SPICE) tolerated candesartan better than an ACEI (pp. 
98-100). 
Granger et al. (2000) conducted a double-blind randomization study to determine 
whether patients’ intolerant of ACEIs could tolerate ARBs.  There were 90 different 
study sites in seven different countries to obtain a broad perspective, as well as to create a 
registry of patients who could not tolerate ACEIs.  Participants in the study initially 
received either 4 mg of candesartan or 4 mg of a placebo.  The medication dosages were 
then titrated to 8 mg at 2 weeks and doubled in mg after 4 weeks.  If patients continually 
tolerated the medications, then dosages were increased to 16 mg.  The titration of 
medication from beginning to end lasted a total of 12 weeks.  They reported that 82.7% 
of the participants tolerated the titration of the candesartan and completed the 12-week 
program. In addition, they reported that patients taking the medication as opposed to the 
placebo were hospitalized less frequently (18.7% vs 12.8%) (pp. 611-613).  
Savarese et al. (2013) conducted a meta-analysis of 26 trials comparing ACEIs 
and ARBs in patients with high cardiovascular risks but without heart failure.  They 
found that the combination of medications benefited patients with an increased chance of 
developing the disease.  These researchers also reported that the literature indicated 
ARBs were beneficial in the reduction of mortality and morbidity in patients who 
experienced a contraindication to ACEIs (pp. 133-140). 
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Aldosterone Antagonists 
Aldosterone antagonists (AA) are diuretics that block the effects of aldosterone in 
the body, specifically via regulation of fluid volume.  This is a major factor in heart 
failure patients because they are susceptible to volume overload.  Spironolactone and 
Eplerenone are commonly used aldosterone antagonists (Maron & Leopold, 2010, pp. 2-
3).   
Several studies cite the combination of Aas, BBs, and ACEIs as being beneficial 
to heart failure patients.  Aas are associated with decreases in mortality and re-
hospitalizations.  Hyperkalemia is an associated drawback to using these medications 
(Nappi & Sieg, 2011; Rocha & Williams, 2002).  The AHA and ACCF recommend Aas 
in heart failure patients with an EF < 35% to reduce morbidity or mortality.  They are 
also recommended in patients following acute myocardial infarctions that have a reduced 
EF of 40% or less (Yancy et al., 2013, p. e268).   
Marcy and Ripley (2006) reviewed the functions, benefits, and adverse events that 
might occur while using aldosterone antagonists in heart failure.  Spironolactone and 
eplerenone were identified as the available aldosterone antagonists used in healthcare.  
The authors reported that Aas are a pivotal part of treatment in conjunction with other 
heart failure treatments.  They reported, as previously cited, that the renal function of 
heart failure patients and risk of hyperkalemia should be routinely monitored (pp. 49-56). 
Miller and Alvarez (2013) reviewed literature in support of Aas and guidelines to 
support their use.  The authors identified three major trials: the Randomized Aldactone 
Evaluation Study (RALES), the Eplerenone Postacute Myocardial Infarction Heart 
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Failure Efficacy and Survival Study (EPHESUS), and the Eplerenone in Patients with 
Systolic Heart Failure and Mild Symptoms Study (EMPHASIS) (p. E49).   
Pitt et al. (1999) conducted RALES to determine whether 25 mg of 
spironolactone affected patients at risk for death with end-stage heart failure.  The study 
included 1663 patients, 822 of which received the initial dose of spironolactone 25 mg 
daily, and 841 patients receiving the same dosage of a placebo daily.  The medication 
dose was doubled at 8 weeks if the patients tolerated the medication without exhibiting 
signs and symptoms of hyperkalemia.  If the patient did not tolerate the medication, the 
medication dosage was titrated down to a smaller dose.  The study ended when death 
occurred.  The authors reported that spironolactone was associated with the heart failure 
patients’ reduced risk for death by 30% but also reduced the risk of hospitalizations 
caused by cardiac issues by 35% less than the placebo group.  The author also reported 
that their study further reinforced the premise that ACEIs were insufficient to suppress 
the aldosterone hormone, but that Aas had a pivotal part of treating heart failure, as well 
(pp. 709-716).   
Pitt et al. (2003) conducted the EPHESUS to evaluate eplerenone and its effect on 
morbidity and mortality of heart failure patients who had experienced a myocardial 
infarction.  Six thousand six hundred and forty-two patients participated in the study, 
with 3313 receiving eplerenone and 3319 receiving the placebo.  An initial dose of 25 mg 
was given to the eplerenone and placebo group.  The participants also received optimal 
medications in conjunction with the study meds. The study ended when death occurred 
among the participants.  The authors reported that more deaths occurred in participants 
who received the placebo than those who received eplerenone.  Cardiovascular-related 
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issues caused death in both groups.  The authors reported that participants in the 
eplerenone group (12.3%) experienced fewer deaths resulting from cardiac causes than 
participants in the placebo group (14.6%) (pp. 1309-1321). 
Zannad et al. (2011) also conducted a study of the drug eplerenone to determine 
its effect on patients (n = 2,737) with left-sided heart failure exhibiting symptoms. There 
were two study groups: eplerenone group (n = 1364) and a placebo (n = 1373).  The 
patients also received additional pharmacologic systolic heart failure therapy.  
Participants initially received a daily dose of 25 mg of eplerenone or the placebo.  If the 
patient tolerated the medication, the daily dosage was doubled.  The end point primary 
outcomes of the study were either death or hospitalization.  The authors reported that 
patients taking eplerenone had a smaller risk of deaths and hospitalizations than those 
receiving a placebo.  There were fewer deaths in the eplerenone group (18.3%) than in 
the placebo group (25.9%) (pp. 11-20).   
Beta Blockers  
 BBs block beta-adrenergic receptors in the body.  They decrease the workload of 
the heart by slowing the pulse and lowering blood pressure.  These medications are a 
common treatment option for patients with hypertension (AHA, 2015c).  They should 
also be used in conjunction with other medications when treating heart failure (Chavey, 
2000; Gheorghiade, Colucci, & Swedberg, 2003).  The AHA and ACCF recommend BBs 
in all patients with an EF < 35%.  They are also recommended in patients with a heart 
attack and an EF < 35% to prevent heart failure (Yancy et al., 2013, p. 261).  In previous 
studies, authors have cited a relationship between BBs and a reduction of mortality, 
improved quality of life, and a reduction in hospital readmissions. 
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Chang, Yang, Freeman, Hlatky, and Go (2013) performed a study to determine 
their effectiveness in patients (n = 668) with heart failure and chronic kidney disease.  
Pharmacy databases were used to collect data on medication utilization among the 
participants in the study. Participants were included in the study if pharmacy data 
revealed BB utilization among patients twelve months or longer.  The authors reported 
that patients beyond 80 years of age seldom initiated the medication, and participants 
who initiated them into their pharmacotherapy regimen reduced their risk of death and 
hospitalization (pp. 176-181). 
Packer et al. (2001) analyzed the survival rate of patients with end-stage heart 
failure taking carvedilol.  The study’s patients (n = 2,289) were divided into a carvedilol 
(n = 1156) and placebo group (n = 1133).  Both groups received a dose of 3.125 mg two 
times a day for 14 days.  Medications dosages were doubled every 2 weeks if the patients 
tolerated the titrations until the goal of 25 mg twice daily was achieved.  Death and risk 
of death or hospitalization were the end-points of the study. The authors reported that 
carvedilol was tolerated well by the patients.  Patients in the placebo group had to 
discontinue their treatment early as opposed to patients in the carvedilol because of 
adverse effects.  The authors also reported that adding carvedilol to the patients’ 
medication regimen produced substantial effects towards their survival.   
The rate of death in patients receiving carvedilol was reduced by 35%.  The risk of death 
and hospitalizations were reduced by 24% (pp. 1651-1657).   
Taneva and Caparoska (2016) conducted a study on chronic heart failure patients 
to determine whether BBs had an impact on death and death and/or hospitalizations 
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related to cardiovascular issues.  One hundred and thirteen patients were evaluated for 2 
years. The patients were divided into participants receiving a beta blocker and a control 
group.  Patients in the beta blocker group received a beta blocker along with conventional 
heart failure therapy. Conventional therapy was the only treatment received in the control 
group.  Conventional therapy included diuretics, cardiac glycoside, and ACEIs.  The beta 
blocker group was further divided into three subgroups with each group receiving a 
different beta blocker: metoprolol, bisoprolol, and carvedilol.  The authors reported that 
the risk of death was reduced by 34% in the beta blocker group, and the combination of 
death and/or hospitalization was also reduced by 40% (pp. 94-97).   
Gomez et al. (2011) performed a prospective study (n = 1,085) to determine the 
relationship between death and incidence of disease of heart failure patients with a 
preserved systolic function and the treatment of BBs.  The study took place over a course 
of 5 years.  The medications under review were bisoprolol and carvedilol.  Pharmacy 
databases were utilized to monitor compliance as well as other routine heart failure 
medications.  The authors reported that morbidity, mortality, and hospital admission were 
all reduced by BBs.  Patients with newly diagnosed preserved systolic function and being 
treated with BBs experienced a reduced risk of death by 28% for those related to all 
causes and by 41% for those related to the heart. The incidence of the disease was also 
reduced as evidenced by the reduced risk of hospitalization (24%) and reduced risk of 
repeat admission to the hospital (23%) (pp. 51-55). 
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Utilization of Evidence-Based Heart Failure Guidelines and  
Its Impact on Morbidity and Mortality  
Gislason et al.’s (2007) retrospective study evaluated evidence-based 
pharmacotherapy in heart failure patients.  They examined the relationship between 
initiation, underdosing, or early termination of pharmacotherapy and the underuse of 
pharmacotherapy.  In this study, the medical treatment of adults (n = 107,092) 
hospitalized for the first time with heart failure and discharged between 1995 and 2004 
were reviewed.  Medical treatments were examined for BBs, ACEIs and ARBs, 
spironolactone, and statins.  The authors used logistic regression to assess trends between 
initiation of treatment and patient mortality.  Multivariable analysis was used to assess 
the trends between mortality and break in therapy for 90 or more days.  The authors 
reported an increase in initiation of medical treatment between 1995 and 2004: ACEIs 
and ARBs (35.9% to 49.6%), BBs (12.1% to 42.7%), spironolactone (9.8% to 24.9%), 
and statins (2.0% to 26.9%).  In addition, clinicians were routinely prescribing 
medications below the recommended doses and failing to increase the dosages during 
long-term treatment.  The authors also reported that the persistent use of treatment 
contributed to a decrease in mortality between 1995 and 2003 (38.7% to 34.5%) (p. 739).   
Asghar and Rahko (2010) compared adherence to 2005 ACCF/AHA guidelines 
when utilizing implantable cardioverter-defibrillators (ICD), cardiac resynchronization 
therapy (CRT), and medication therapy between heart failure clinicians and general 
cardiologists.  The authors retrospectively reviewed charts of adult patients seen in a 
heart failure clinic (n = 324) or general cardiologist clinic (n = 239) between 2005 and 
2006.  The authors looked for patients who had chronic left ventricular dysfunction 
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confirmed by imaging and stage C heart failure.  Three hundred and twenty-four charts 
met criteria in the heart failure clinic, and 239 charts met criteria in the general 
cardiologist clinic.  They reported that both the heart failure clinicians and general 
cardiologists followed the guidelines for CRT (86% vs. 81%) and placement of ICDs 
(77% vs. 74%).  There was a difference however in the heart failure clinicians and 
general cardiologists’ implementation of guidelines when treating heart failure (97% vs. 
82%).  Patients receiving guideline-recommended medicines had a > 35% improvement 
in their EF (pp. 65-69). 
Fonarow et al. (2011) investigated the potential impact of failing to comply with 
guidelines to implementing optimal evidence-based therapies on heart failure mortality.  
The authors identified six evidence-based guideline-recommended therapies that reduced 
death in those affected by the disease.  The recommended therapies included 
conventional heart failure therapy along with hydralazine/isosorbide dinitrate, CRT, and 
ICD.  A representative sample of patients (n = 2,644,800) was drawn from inpatient and 
outpatient heart failure registries as well as studies that examined heart failure quality of 
care.  They compared the patients who were eligible for and treated with the 
recommended therapies against those patients who were also eligible for treatment but 
were not treated.   
Researchers reported that a significant number of eligible patients did not receive 
the recommended therapies.  A significant number of eligible patients did not receive 
hydralazine/isosorbide dinitrate (92.7%) while the lowest number of eligible patients did 
not receive recommended BBs (14.4%).  Additionally, a significant number of eligible 
patients did not receive an ACEI or an ARB (20.4%), an AA (63.9%), CRT (61.2%), or 
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ICD (49.4%).  The results indicated that full implementation of all six therapies had the 
potential to prevent 67,996 deaths a year, and the implementation of evidence-based BBs 
alone had the potential to prevent 21,357 deaths (pp. 1025-1027). 
Majumdar et al. (2004) examined the benefits of using high-dose ACEIs, BBs, 
and digoxin in 3,164 patients with advanced heart failure in 19 different countries 
between 1992 and 1994.  Medication utilization was the dividing factor between the 
groups.  Ninety-one percent of the patients analyzed in the study were still on their initial 
treatment regimen.  The results revealed that patients receiving all evidence-based 
therapies had a reduced rate of death and hospitalization (12%) at 1 year as compared to 
those who received only low-dose ACEIs.  The results also indicated that patients taking 
only low-dose ACEIs plus digoxin were an increased risk for all-cause mortality (pp. 
694-699).   
Yancy et al.’s (2010) prospective study assessed the utilization of ACCF/AHA 
guideline-recommended therapies in U.S. outpatient cardiology clinics between 2005 and 
2007.  The authors assessed for the following measurements: (a) pneumococcal vaccines, 
(b) utilization of isosorbide dinitrate/ hydralazine specifically in Black patients, (c) statin 
and antiplatelet therapy, (d) cholesterol levels, (e) smoking cessation counseling, and (f) 
blood pressure controls.   
The results of the study showed that the mean adherence for HYD/ISDN was 
7.3%, and more than 71% of the outpatient practices failed the HYD/ISDN measurement.  
Outpatient practices were also significantly deficient in the other measurements.  The 
results ranged from as low as 1.2% for pneumococcal vaccination to 80.8% for blood 
pressure controls.  The results of the study indicated that outpatient practices were 
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deficient in their conformity to guideline-recommended heart failure therapy and that 
better processes were needed to promote adherence to guideline-recommended therapy 
(pp. 255-260).   
The first part of this literature review provided an overview of the four 
pharmacological classes used in the ACCF/AHA’s guidelines in disease management. 
The four classes consisted of ACEIs, BBs, ARBs, and Aas.  This section explored the 
function of each pharmacological class and studies that supported their use in disease 
management.  Studies were also provided on the utilization of the pharmacological 
classes in treatment and their impact on morbidity and mortality.  The second part of the 
review provided below discussed the guidelines and their impact on hospital admissions 
and readmissions.  
Utilization of Evidence-Based Heart Failure Guidelines and Its Impact on  
Hospital Admissions and Readmissions 
Numerous programs and strategies have been implemented to reduce 
readmissions; however, the numbers of readmissions in healthcare institutions remain 
steady.  The hospital is a central location for heart failure patients to receive care.  
Hospitals are sometimes the first stop for patients to receive heart failure diagnostics and 
to learn about living with heart failure.  These offerings are often insufficient.  After 
discharge, patients still need to be monitored and medications should be adjusted 
accordingly.  If evidence-based therapies are not taken into account, patients are put at an 
increased risk for readmission. 
Gheorghiade, Vaduganathan, Fonarow, and Bonow (2013) offered insight into 
strategies that may help reduce readmissions.  They discussed the influence symptoms 
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had on readmissions, monitoring heart failure patients and their disease, and utilization of 
evidence-based therapies in their treatment.  Further, they classified a low ejection 
fraction and the symptom of congestion as being high risk for readmission.  One can 
conclude that hospitals could reduce readmissions by performing comprehensive patient 
assessments to evaluate not only the physical characteristics and comorbidities of the 
patients but the social circumstances that might contribute to readmissions, as well.  The 
authors submit that though the patient’s hospital admission was important, the post-
discharge phase was a vulnerable period for the patient.  As such, patients and their 
families play significant roles in bridging that transitional phase between the hospital and 
home.  Through collaborative efforts between the patient and the healthcare team, 
readmissions are expected to decline (pp. 395-401). 
Kociol et al. (2012) explored the national trends of hospitals and heart failure 
readmissions.  One hundred randomly selected hospitals were contacted via telephone 
that participated in the Get with the Guidelines-Heart Failure (GWTG-HF) quality 
improvement program, the extent to which the program had any impact on the reduction 
of heart failure readmissions.  The program aims to improve the care patients receive in 
hospitals by supporting consistent use of today’s evidence-based research (AHA, 2015b).  
The survey addressed three vital processes that affect readmissions: (a) the care patients 
receive while in the hospital, (b) the care patients receive at discharge, and (c) the overall 
quality of care received.  The authors used linear regression to analyze the relationship 
between those processes and the readmission rates of the surveyed hospitals.  Results of 
the study indicated that the hospitals did participate in strategies to improve inpatient care 
and the overall quality of care received.  The results also indicated care received at 
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discharge were associated with a reduction of readmission rates (Kociol et al., 2012, pp. 
681-685).   
Heidenreich et al. (2012) also performed a study to determine whether the 
program improved processes of care in hospitals that used the program as opposed to 
hospitals that did not. The hospitals’ enrollment period was 2006 to 2007.  The study 
included 4,460 hospitals.  Of those 4,460 hospitals included in the study, 215 (5%) of the 
hospitals participated in the GWTG-HF and the other 4,245 (95%) did not participate in 
the study.   
The hospitals had to address four processes valuable to the treatment of heart 
failure as determined by CMS; they were (a) assessment of the patient’s left ventricular 
function, (b) use of an ACEI or ARB to treat left ventricular systolic dysfunction or a 
reduced EF, (c) discharge teaching, and (d) counseling for smoking cessation.  The 
researchers used Pearson X2, Wilcoxon rank-sum tests, and multivariable logistic 
regression analyses to analyze the data.  The results indicated hospitals that participated 
in the program reflected better scores in regards to the documentation of left ventricular 
ejection fraction, utilization of recommended medications, and teaching at discharge.  A 
difference was not seen among counseling for smoking cessation between the two sets of 
hospitals.  The results also indicated that hospitals participating in the program had lower 
all-cause readmission rates than hospitals that did not participate in the program (pp. 37-
39). 
Yoo et al. (2014) performed a retrospective, observational study to examine 
whether Korean hospitals adhered to guidelines when treating systolic heart failure.  The 
study population included 1,297 patients with admittance to 23 university hospitals in 
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2009.  The authors determined compliance by assessing for the use of three 
pharmacological classes: (a) ACEI/ARB, (b) BB, and (c) AA.  They also examined the 
clinical outcomes of the patient, which included (a) 90-day mortality, (b) 1-year 
mortality, (c) re-hospitalizations, and (d) mortality and re-hospitalizations.  The study 
population was divided into two groups: patients with good guideline adherence and 
patients with poor guideline adherence.  The authors defined good guideline adherence as 
the utilization of greater than or equal to 50% of the pharmacological classes, while bad 
guideline adherence involved utilization of less than 50% of guideline adherence to the 
pharmacological classes.  
The results of the study were as follows: (a) ACEI or ARB were adhered to the 
most in treatment at 89.7%; (b) BB’s were second to be adhered to at 69.2%; and (c) the 
AA’s were third to be adhered to at 65.9%.  Results indicated that overall there was good 
adherence to the three pharmacological classes.  Patients with good guideline adherence 
enjoyed a survival rate of 96.7% and a re-hospitalization rate of 62.3%, as opposed to 
patients with bad guideline adherence who experienced a survival rate of 89.8% and a re-
hospitalization rate of 56.4% (Yoo et al., 2014, pp. 1-7). 
Krantz et al.’s (2011) prospective study examined evidence-based heart failure 
medications in hospitalized patients from admission to discharge in an attempt to reduce 
death and hospitalizations.  The study population consisted of 9,474 patients admitted to 
hospitals enrolled in the GWTG program.  Researchers assessed for the utilization of 
three pharmacological classes: ACEIs/ARBs, BBs, and Aas.  Prior to hospital admission, 
a significant number of patients were eligible for recommended therapies.  Ninety-three 
percent of the patients met eligibility for a BB. This was followed by more than 70% of 
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the patients being eligible for the two remaining pharmacological classes.  During 
hospital admission, 72.6% of eligible patients were given BBs, and an ACEI /ARB was 
also administered to 65.3% of the eligible patients.  Aldosterone antagonists were the 
least pharmacological class given to eligible patients at 15.6%.  More than 90% of the 
eligible patients received a BB or an ACEI/ARB at discharge.  The least number of 
eligible patients (32.2%) received an AA.  The initiation of the three pharmacological 
classes at admission were predictors of continued use at discharge of the patients (pp. 
1818-1823). 
Calvin et al. (2012) reported the results of the Heart Failure Adherence Retention 
Trial (HART), which studied the adherence of both physician and patient to evidence-
based guidelines for heart failure.  Two classifications of medications were primarily 
examined: (a) ACEI/ARBs, and (b) BB.  They defined physicians as being non-adherent 
if any of those medications were prescribed when contraindicated, or physicians failed to 
prescribe any of those medications to patients without contraindications.  The authors 
determined patient adherence by using MEMS electronic pills caps to measure the 
number of times patients opened their medication bottles and by comparing those 
numbers to medication regimens prescribed by the physician.  Patients were considered 
adherent if they took their medication more than 80% of the time.   
The study consisted of 692 patients recruited from hospitals throughout the 
greater Chicago area.  Patients were recruited with a systolic dysfunction or EF of less 
than 40%.  The authors reported that 63% of physicians were adherent to guidelines when 
treating heart failure.  There were more patients with contraindications on therapies than 
those without contraindications that should have been recommended therapies.  BBs were 
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prescribed to 35 out of 51 (68.6%) patients with contraindications and ACEIs/ARBs were 
prescribed to 40 out of 54 (74.1%) patients with contraindications.  The authors also 
reported that 213 out of 581 (37%) patients did not consistently take their prescribed 
medications; however, the overall non-adherence rate for both physicians and patients 
was 59%.  An interesting finding of the study was that minority status of the patients was 
associated with their non-adherence.  Physician non-adherence was associated with four 
factors: minority status of the patient (which was not defined in the study), comorbidities 
of the patients, age of the patients, and advanced stages of heart failure (Calvin et al., 
2012, pp. 73-78). 
Summary 
This literature review discussed research related to evidence-based guidelines for 
the treatment of heart failure, studies related to the utilization of evidence-based 
guidelines in the treatment of heart failure, and studies related to heart failure 
readmissions.  The literature review provided research that supported the utilization of 
evidence-based pharmacologic treatment in practice and its impact on patients’ outcomes 
(Asghar & Rahko, 2010; Calvin et al., 2012; Fonarow et al., 2011; Gislason et al., 2007; 
Majumdar et al., 2004; Yancy et al., 2010).  Asghar and Rahko (2010) and Yancy et al. 
(2010) specifically looked at the utilization of ACCF/AHA pharmacological guidelines in 
the pharmacological treatment of heart failure patients.  Though research demonstrated 
positive outcomes for patients receiving evidence-based pharmacotherapy, researchers 
reported varying degrees of conformity to use of evidence-based guidelines in practice.  
Several studies in the literature occurred in hospitals and clinics in the United States and 
other countries.  The limitation of this review was the lack of research on utilization of 
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the guidelines in the state of Mississippi.  This finding supports the study’s research 
question of determining to what extent are Mississippi hospitals adhering to evidence-
based pharmacological management guidelines for the management of heart failure.  
Pharmacologic treatment not specific to the ACCF/AHA guidelines was also 
explored.  The authors reported that patients did receive an initial treatment of evidence-
based pharmacotherapy; however, some clinicians did not increase doses as 
recommended.  In addition, some patients eligible for evidence-based pharmacotherapy 
did not receive them. 
Gislason et al. (2007) evaluated evidence-based pharmacotherapy in heart failure 
patients and discovered that patients received insufficient dosages of the recommended 
therapies.  The authors also reported that the initial dosages remained the same onward.  
Another key finding the authors reported in the study were that age, living arrangements, 
and socioeconomic factors all played a part in medication persistence.  Patients of 
advanced age and who lived alone reflected poorer medication persistence.  Additionally, 
the socioeconomic factor of increased medication costs also contributed to medication 
persistence (p. 739)  
The study completed by Majumbar et al. (2004) produced similar results in 
regards to medication dosages.  The authors performed a secondary analysis of the 
Assessment of Treatment with Lisinopril and Survival Trial (ATLAS), a study that 
examined the effect low and high doses of ACEIs had on death and incidents of the 
disease (Packer et al., 1999).  The results of the study showed that patients receiving 
higher doses of ACEIs along with the evidence-based dosages of other heart failure 
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therapies had greater benefits, such as a reduction in mortality or hospitalization (pp. 697-
701). 
Fonarow et al.’s (2011) study did not offer probable explanations as to why there 
was not conformity to evidence-based heart failure therapies; however, the study 
quantified current treatment gaps and the number of preventable deaths with the 
implementation of therapies.  The authors reported that a significant number of eligible 
patients (n = 2,644,800) were not being treated with the recommended ACEIs/ARBs (n = 
501,767), BB (n = 361,809), or Aas (n = 385,326).  The numbers were also significant for 
the number of deaths related to not receiving the recommended therapies.  The authors 
reported that the deaths of these patients (n = 67,996) be prevented if patients received 
the optimal implementation of guideline-recommended treatment (pp. 1025-1027). 
Several of the studies supported the premise that evidence-based therapies in the 
management of heart failure patients were able to increase survival rates and reduce 
hospital readmissions (Gheorghiade et al., 2013; Heidenreich et al., 2012; Kociol et al., 
2012; Krantz et al., 2011; Yoo et al., 2014).  Heidenreich et al. (2012), Kociol et al. 
(2012), and Krantz et al. (2011) studied the impact using the GWTG program had on 
readmissions and reported that use of the guidelines contributed to the reduction of heart 
failure readmissions.  Calvin et al.’s (2012) study focused on physician and patient 
adherence to evidence-based guidelines in the Chicago area.  The results indicated the 
both patients and physicians had an issue with adherence to guideline-recommended 
therapies.  
Overall, the literature lacks research about the evidence-based pharmacotherapy 
used to treat heart failure patients in Mississippi.  Identifying whether Mississippi heart 
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failure patients are receiving evidence-based therapies might be the start to filling the gap 
regarding the utilization of evidence-based pharmacotherapy in Mississippi.  This 
understanding might help guide development of strategies for encouraging adherence to 
practice guidelines with the possibility of curbing costs associated with readmission rates 
of Mississippi heart failure patients.  Studies in different geographic regions are also 
important because they can help identify the needs of patients and physicians specific to 
those regions.  Information from that study can also assist in the creation of policies and 
programs that tailor to the needs of people in those communities (Casper et al., 2010, p. 
299). 
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CHAPTER III  - METHODOLOGY 
Introduction 
Chapter III outlines the steps taken for implementation of the current study.  
Provided is information on the setting, sample, steps taken to protect participants, data 
collection techniques, and how data analysis was engaged.  The researcher conducted an 
exploratory study to evaluate the relationship of adherence to evidence-based guidelines 
for pharmacologic management by selected Mississippi hospitals and their hospital 
readmission rates.  A retrospective design was used in this study, as it offered insight into 
the relationship between readmissions of heart failure patients and adherence to the 
national guidelines for the pharmacologic treatment of heart failure. 
Setting 
The setting for this exploratory study was a 400-bed health care institution located 
in the southeastern region of the United States.  The selected healthcare institution is one 
of the largest medical systems in that state and region, offering two hospitals and a 
variety of healthcare clinics.  Several other hospitals were approached for inclusion, but a 
plethora of barriers prevented their participation. Although it cannot be substantiated, it 
seemed as though a few of the approached hospitals were reluctant to have records 
evaluated that would have determined their quality of congestive heart failure treatment 
and care. 
Sample 
The researcher collected sample data for this study from a database of medical 
records of patients with heart failure seen between January 2011 and June 2014.  The 
sample data were used to measure adherence to pharmacotherapy recommendations.  
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This time period was chosen because readmission data received from data.medicare.gov 
(2015b) specified these date ranges as the dates of analysis for readmissions in 
Mississippi.  Date ranges are also a significant factor in retrospective studies.  A 4-year 
span was chosen to maximize the study’s efficacy by increasing the number of 
hospitalizations that qualified as readmissions.  The researcher limited the study to the 
first 30 days of the patient’s index hospitalization and readmissions included in that 
period.   
Patient inclusion criteria for this study included the following components: 18 
years of age and older with a diagnosis of heart failure as identified by the International 
Classification of Disease (ICD – 9) Codes for heart failure (Table 1).  ICD-9 codes were 
used because hospitals did not begin using ICD-10 codes until October 2015.  
Hospitalizations that met inclusion criteria were identified by a list of 30-day 
readmissions provided by administrators at the healthcare institution. 
The researcher determined through a power analysis 80 medical records would be 
an adequate sample size for this study.  A convenience sample was utilized to select 
subjects.  The researcher was able to collect 31 of the required charts needed for review.  
This limited number of charts was due to chart availability and the limited number of 
staff available to pull an adequate number of charts.  
Protection of Human Subjects 
The University of Southern Mississippi’s Institutional Review Board (Appendix 
B) and the IRB of the selected healthcare institution in Mississippi (Appendix C) 
approved this exploratory study.  There were no known risks to the participants or the 
information the researcher obtained in this study.  The researcher did not recruit any 
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patients but instead used confidential retrospective data only from medical chart reviews.  
Data were collected in a private room provided to the researcher by the healthcare 
institution.  This measure reduced the risk of accidentally disclosing confidential 
information as the medical charts were reviewed.  The researcher ensured that data 
obtained from the records were non-identifiable and kept confidential.  The researcher 
achieved confidentiality by not collecting personal information, such as names, 
addresses, and/or social security numbers.  The researcher also replaced medical record 
numbers with researcher created identification numbers assigned only for this study.  
Data were entered the same day it was collected as well as stored on a laptop with 
password-protected software.  The researcher took the protection of data a step further by 
securing the laptop and data abstraction tool, used to collect data, in a locked file cabinet. 
Data Collection 
Following USM IRB approval and approval from the selected healthcare 
institution, data for this study were obtained by the researcher from medical records at the 
approved healthcare site.  The researcher requested permission to access the medical 
records of patients with the primary admission diagnosis of heart failure.  The researcher 
created a simple data abstraction tool (Appendix A) to collect data on the variables of 
interest: demographic variables and clinical variables.  Data abstraction tools add to the 
validity of retrospective studies by guiding data collection and ensuring that data is 
collected in a uniform manner (Schwartz & Panacek, 1996, p. 123).  A well-designed 
data abstraction tool limits the chance of missing data, increases the likelihood accurate 
data is collected and promotes the analysis of accurate data (Banks, 1998, p. 164).  The 
researcher utilized the data collection tool to determine whether the ACCF/AHA 
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guidelines were adhered to by seeking documentation that included the four 
pharmacological classes in the patients’ treatment at admission and discharge and then 
again at the patients’ readmission and discharge.  
The demographic variables of interest included age, gender, and ethnicity.  Age, 
gender, and ethnicity of the patients were obtained from the patients’ admission 
demographic paperwork.  Age was confirmed by the patients’ date of birth.  Gender was 
defined as the patients’ biological construct: male or female.  This information was 
designated on the patients’ chart. 
The clinical variables of interest included admission date, discharge date, and 
readmission date, stage of heart failure, ICD-9 code diagnosis of heart failure, 
comorbidities (diabetes, hypertension, myocardial infarction, atrial fibrillation, ischemic 
heart disease, hyperlipidemia, anemia, chronic kidney disease, and chronic obstructive 
pulmonary disease), height, weight, lab findings (blood urea nitrogen (BUN), creatinine, 
potassium, brain natriuretic peptide (BNP), hemoglobin a1c, and hemoglobin), admission 
and discharge vital signs, heart failure medications at index  admission/discharge and 
readmission/discharge , and smoking status (current smoker, past smoker, and never 
smoked).  The researcher also collected the payer sources for this hospitalization of the 
sample participants, which may include Medicare, Medicaid, private insurances, and non-
insured.  The data were entered into Excel and imported into a statistical software 
package for data analysis. 
ICD-9 codes were either identified on the patients’ demographic admission 
paperwork or the case manager’s discharge planning notes.  When the ICD-9 code for 
heart failure was not available to confirm the patients’ diagnosis admission of heart 
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failure, the researcher then reviewed the physician’s dictated history and physical for the 
inclusion of the diagnosis of heart failure in the reason for admission diagnoses.  The 
researcher used the criteria displayed in Table 2 to determine the stage of heart failure 
among the patients. The confirmation of stage C heart failure among the patients was 
confirmed by the emergency room’s documentation of the patients’ heart failure 
symptoms exhibited upon admission, as well as the physician’s documentation in the 
history and physical of the patients’ heart failure symptoms exhibited upon admission.  
Information regarding patients’ height, weight, lab values, comorbid conditions, 
vital signs, and smoking status were obtained from chart reviews.  Height and weight 
were obtained from the patients’ admission paperwork.  Lab values were obtained at 
admission from the patients’ laboratory paperwork.  Index admission and discharge vital 
signs were obtained at the patients’ initial admission from the graphic’s section in the 
patients’ chart.  The researcher focused primarily on patients’ blood pressure and pulse.   
The selected comorbid conditions on the data abstraction were identified in the 
ACCF/AHA guidelines as being comorbid conditions that commonly affect heart failure 
patients (Yancy et al., 2013, p. e294).  The patients’ comorbid conditions were obtained 
from the physician’s dictated history and physical, consultation notes, and discharge 
notes.  Smoking status was obtained from the physician’s dictation of the patients’ 
smoking status in either the patients’ history and physical or consultation notes.  The 
patients’ payor sources were also identified by the patients’ demographic data. 
Finally, the patients’ medication information was obtained from the medication 
lists at admission and discharge and again from the medication lists at readmission.  Each 
class of medication was recognized by utilizing a list created by researcher of commonly 
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used medications according to each medication class. The referral list is provided in 
Table 3. 
Table 3  
Common Heart Failure Medication Classes  
ACEI BB ARBS AA 
 
- end in pril 
 
- end in lol 
 
- end in tan 
 
 
Benazepril 
(Lotensin) 
 
Acebutolol 
(Sectral) 
 
Candesartan 
(Atacand) 
 
Eplerenone 
(Inspra) 
Captopril 
(Capoten) 
Atenolol 
(Tenormin) 
Eprosartan 
(Teveten) 
Spironolactone 
(Aldactone) 
Enalapril 
(Vasotec/Epaned) 
Betaxolol 
(Kerlone) 
Irbesartan 
(Avapro) 
 
Fosinopril (Monopril) Bisoprolol 
Fumarate (Zebeta) 
Losartan (Cozaar, 
Hyzaar) 
 
Lisinopril 
(Prinivil/Zestril) 
Carvedilol 
(Coreg) 
Olmesartan 
(Benicar) 
 
Moexipril 
(Univasc) 
Esmolo 
(Brevibloc) 
Telmisartan 
(Micardis) 
 
Perindopril 
(Aceon) 
Lebetalol 
(Trandate) 
Valsartan 
(Diovan) 
 
Quinapril 
(Accupril) 
Metoprolol 
(Lopressor) 
  
Ramipril 
(Altace) 
Nadolol 
(Corgard) 
  
Trandolapril 
(Mavik) 
Nebivolol 
(Bystolic) 
  
 Penbutolol 
(Levalol) 
  
 Propranolol 
(Inderal LA, Inderal 
XL) 
  
Adapted from American College of Cardiology, n.d..; Ogbru, 2016a, 2016b, 2016c. 
Data Analysis  
The researcher used the Statistical Package for the Social Science (SPSS) 
software version 23 to analyze the collected data.  Statistical analysis of the data helped 
the researcher answer the study’s research questions by (a) determining the extent to 
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which select Mississippi hospitals adhering to evidence-based pharmacological 
management guidelines for management of congestive heart failure, and (b) determining 
the relationship between adherence to guidelines for pharmacologic management of heart 
failure and readmission to hospital for select Mississippi hospitals. 
First, the researcher utilized descriptive statistics to analyze the patient’s 
demographic data.  Examples of descriptive statistics used in this study are the measures 
of central tendency and frequency distribution.  Mean was the primary measure of central 
tendency used in this study.  The measures of central tendency provide an overall 
description of the sample’s average age, gender, and race (LoBiondo-Wood & Haber, 
2010, pp. 314-315).  The frequency distribution displays the number of times (and 
percentage) each of the pharmacological classes was noted in the patients’ medication list 
at the index admission and discharge and readmission.   
The researcher also utilized inferential statistics to analyze the collected data.  
Inferential statistical analysis helped the researcher determine if there is a relationship or 
difference between variables.  Research question one and two analysis consisted of a t-
test and independent samples t-test.  In this study, the researcher is trying to determine 
whether the utilization of evidence-based heart failure pharmacologic guidelines have an 
impact on heart failure readmissions.  
 
 43 
CHAPTER IV – DATA ANALYSIS 
Introduction 
The purpose of this study was to explore the relationship of adherence to 
evidence-based guidelines for pharmacologic management by selected Mississippi 
hospitals and their hospital readmission rates. Chapter II discussed the literature 
supporting adherence to evidence-based guidelines and the impact it had on readmissions. 
Chapter III discussed the methods used to collect data and introduced the statistics that 
would be used with the Statistical Package for the Social Science to analyze the data.  
Chapter IV presents the results of data analysis.  The unit of analysis for this study was 
the re-hospitalizations of the heart failure patients. 
Description of the Sample 
A total of 31 charts were available for review.  The limited number of charts was 
due to lack of chart availability and limited staff available to pull additional charts.  
Descriptive statistics were generated to describe patients whose records were included in 
the analyses. The mean age of patients at admission was 77.7(SD = 11.3) years. 
Frequencies were generated to describe the sex and race of the patients.  The study 
included 15 females and 16 males.  The study consisted of 24 Caucasians, 6 African 
Americans, and 1 American Indian.   
Clinical Data 
Frequencies and percentages were generated to describe the admitting diagnoses 
based on ICD-9 codes or presentation of symptoms discussed in chapter I and III.  Only 6 
(19.4%) of the patients in the study had an ICD-9 code documentation of heart failure.  
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The other 25 (80.6%) patients had a confirmed diagnosis of heart failure by physician 
documentation. 
All of the patients (N = 31) in this study were identified as having stage C heart 
failure, or as having the presence of heart disease while exhibiting the symptoms of heart 
failure.  Means and standard deviations were generated to describe the weight in 
kilograms, the height in inches, blood pressure (mmHg), and pulse.  The mean height was 
67.65 (SD = 3.77) inches and the mean weight was 89.23 (SD = 26.40) kilograms. 
The review of vital signs is an integral factor in the management of heart failure 
because they help to determine whether the patient’s hypertension is adequately 
controlled.  Uncontrolled hypertension is one of the risk factors for heart failure as well 
as one of the factors that can lead to worsening heart failure (Dumitru & Baker, 2016). 
The mean systolic blood pressure upon admission was 140.45 (SD = 33.48).  The 
mean diastolic blood pressure upon admission was 69.34 (SD = 20.54).  The mean pulse 
upon admission was 83.77 (SD = 22.58). The mean systolic blood pressure upon 
discharge was 133.32 (SD = 20.11).  The mean diastolic blood pressure upon discharge 
was 67.39 (SD = 13.88).  The mean pulse upon discharge was 72. 90 (SD = 15.90).  The 
results are presented in Table 4. 
The frequency of lab values upon admission and discharge were analyzed to 
assess an overview of the patients' labs present at admission and discharge.  The review 
of lab values is pertinent in the treatment of heart failure because they help to monitor 
whether other vital organs, such as the kidneys, are being affected (AHA, 2016).  The 
review of lab values is also important because they relate to whether a patient’s comorbid 
conditions are under control, which also has an influence on readmissions.  If a patient’s 
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comorbid conditions are not adequately controlled, then that can influence the patient’s 
heart failure disease and thus increase the chance of readmission. 
The labs analyzed were BUN, creatinine, BNP, potassium, HgA1C, and 
hemoglobin.  BUN and creatinine are labs used to monitor kidney function (Table 3).  
The kidney function of heart failure patients is especially important because some heart 
failure medications can alter their renal function (Konstam, 2011; Metra, Cotter, 
Gheorghiade, Cas, & Voors, 2012).   
BNP is a significant lab when treating heart failure because it measures how the 
heart is functioning (Doust, Lehman, & Glasziou, 2006).  Potassium is an important lab 
to measure because some heart failure medications predispose patients to hyperkalemia.  
HgA1C is a lab used to monitor whether a diabetic patient's blood sugar levels are 
adequately controlled.  Diabetes can predispose a patient to diabetes as well as worsen 
heart failure in those affected by the disease (Cas et al., 2015).  Finally, it is important to 
monitor the hemoglobin levels of heart failure patients because they are at an increased 
risk for anemia especially when the patient has kidney disease (Anand, 2008; Tang & 
Katz, 2006). The analysis of admitting lab values is presented in Table 4. 
Table 4  
Lab Values 
 N Mean (SD)  
 
BUN 
 
31 
 
43.23 (29.28) 
 
Creatinine 31 2.27 (1.20)  
BNP 30 858.03 (757.98)  
Potassium 30 4.39 (0.69)  
HgA1C 31 89.99 (27.98)  
HgB 31 10.52 (2.51)  
 
 
 46 
The frequency of the comorbid conditions among the patients was also analyzed.  
Many heart failure patients have other comorbid conditions that either predisposed them 
to heart failure or occurred as a result of the disease.  Healthcare professionals have to 
concurrently treat the patient’s heart failure as well as the comorbid condition(s) to 
decrease the worsening of the disease.  The lack of inclusion of a variety of comorbid 
conditions in the study of heart failure has been cited as a potential limitation in the 
sufficient management of the disease (Yancy et al., 2013, p. e299). 
The insufficient inclusion and treatment of comorbid conditions falls under the 
umbrella of non-adherence when considering the utilization of evidence-based 
pharmacological guidelines.  The guidelines cannot be properly adhered to if the patient’s 
other comorbid conditions are not adequately managed.  As stated, some of the patient’s 
comorbid conditions can either predispose them to heart failure if not managed 
appropriately or can contribute to worsening of the disease.  The analysis of comorbid 
conditions is presented in Table 5.  
Smoking status and insurance status of the patients were also analyzed using 
measures of central tendency.  The smoking status of these patients are important to 
determine whether they were self-promoting a better lifestyle.  Current smoking statuses 
have been associated with worsening disease and a decrease in quality of life (Conard, 
Haddock, Poston, & Spertus, 2009).  Three patients (9.7%) were current smokers, 15 of 
the patients (48.4%) had never smoked, 11 patients (35.5%) were past smokers, and data 
was not available for 2 of the patients in the study. The insurances were examined to 
determine whether they might have an influence on the pharmacological treatments 
received. The majority of the patients in the study (71.0%) had only Medicare along with 
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a supplementary private insurance (53.1%). The results of the study showed that 25.8% 
of the patients had Medicare and Medicaid. Only one patient was identified as being non-
insured.   
Table 5  
Comorbid Conditions 
 
Comorbid ConditionsVariables 
 N % 
 
Diabetes 
 
Yes 
No 
 
18 
13 
 
58.1 
41.9 
 
Hypertension Yes 
No 
24 
7 
77.4 
22.6 
 
Ischemic Heart Disease Yes 
No 
16 
15 
51.6 
48.4 
 
Hyperlipidemia Yes 
No 
11 
20 
35.5 
64.5 
 
Anemia Yes 
No 
12 
19 
38.7 
61.3 
 
Chronic Kidney Disease Yes 
No 
19 
12 
61.3 
38.7 
 
COPD Yes 
No 
10 
21 
32.3 
67.7 
 
Atrial Fibrillation Yes 
No 
14 
17 
45.2 
54.8 
 
Myocardial Infarction Yes 
No 
6 
25 
19.4 
80.6 
 
 48 
Research question #1 - To what extent are select Mississippi hospitals adhering to 
evidence-based pharmacological management guidelines for management of heart 
failure?   
The researcher analyzed the frequency of utilization of each pharmacological 
class upon index admission/discharge and readmission/discharge to answer question one.  
The results of the analysis indicated that BBs were the most commonly used 
pharmacological treatments in the management of heart failure.  Patients were either 
prescribed the medication or had sufficient documentation contraindicating the utilization 
of the medication in their pharmacological management.  The frequency of BBs (83.9%) 
remained the same upon admission/discharge and readmissions/discharge 
Table 6  
Frequency of Medication Adherence and Non-Adherence 
Medication 
class 
Index Admission and Discharge Readmission 
Yes No Yes No 
 
ACE Inhibitor 
 
13 (41.9%) 
 
18 (58.1%) 
 
8 (25.8%) 
 
 
23 (74.2%) 
Beta blocker 26 (83.9%) 5 (16.1%) 26 (83.9%) 
 
5 (16.1%) 
Angiotensin 
receptor 
blocker 
 
10 (32.3%) 21 (67.7%) 7 (22.6%) 
 
24 (77.4%) 
Aldosterone 
inhibitor 
8 (25.8%) 23 (74.2%) 10 (32.3%) 21 (67.7%) 
 
Research question #2 - What is the relationship between adherence to guidelines 
for pharmacologic management of heart failure and readmission to select Mississippi 
hospitals?   
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The relationship between adherence to guidelines for pharmacological 
management and readmission was first examined by examining distribution of 
readmissions based on days since index admission (see Table 7).  The first column 
represents the number of days since admission the patients were readmitted, and the 
second column represents the frequency of patients who readmitted on the number of 
days since admission. 
Table 7  
Frequency of Readmission Since Discharge 
  Frequency Percent Valid Percent Cumulative Percent 
Valid 1 2 6.3 6.5 6.5 
3 2 6.3 6.5 12.9 
6 1 3.1 3.2 16.1 
7 3 9.4 9.7 25.8 
8 1 3.1 3.2 29.0 
9 1 3.1 3.2 32.3 
11 1 3.1 3.2 35.5 
12 2 6.3 6.5 41.9 
14 1 3.1 3.2 45.2 
17 3 9.4 9.7 54.8 
22 1 3.1 3.2 58.1 
23 1 3.1 3.2 61.3 
24 2 6.3 6.5 67.7 
26 1 3.1 3.2 71.0 
28 1 3.1 3.2 74.2 
29 1 3.1 3.2 77.4 
30 3 9.4 9.7 87.1 
32 1 3.1 3.2 90.3 
34 1 3.1 3.2 93.5 
36 1 3.1 3.2 96.8 
42 1 3.1 3.2 100.0 
Total 31 96.9 100.0  
 
Next, a t-test was performed to analyze if there was a difference in the means 
between the adherence and non-adherence of the four pharmacological classes.  Lastly, 
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the relationship between adherence to guidelines for pharmacological management and 
readmission was examined using an independent samples t-test looking for a significance 
level of .05.  Each pharmacological class of medication was examined.   
There was no significant difference in the scores for ACEI utilization or 
documentation (M = 18.92, SD = 9.691) and no ACEI utilization or documentation (M = 
17.56, SD = 13.053); t (29) = -.319, p = .752.  There was no significant difference in the 
scores for ACEI2 utilization or documentation (M = 21.00, SD = 11.514) and no ACEI2 
utilization or documentation (M = 17.13, SD = 11.718); t (29) = -.808, p = .426.  There 
was no significant difference in the scores for BB utilization or documentation (M = 
19.12, SD = 11.810) and no BB utilization or documentation (M = 13.00, SD = 9.925); t 
(29) = -1.803, p = .288.  There was no significant difference in the scores for BB2 
utilization or documentation (M = 19.12, SD = 11.810) and no BB2 utilization or 
documentation (M = 13.00, SD = 9.925); t (29) = -1.803, p = .288.  There was no 
significant difference in the scores for ARB utilization or documentation (M = 16.80, SD 
= 10.465) and no ARB utilization or documentation (M = 18.76, SD = 12.300); t (29) = 
.434, p = .667.  There was no significant difference in the scores for ARB2 utilization or 
documentation (M = 14.29, SD = 12.216) and no ARB2 utilization or documentation (M 
= 19.25, SD = 11.437); t (29) = .996, p = .327.  There was no significant difference in AA 
utilization or documentation (M = 17.38, SD = 14.667) and no AA utilization or 
documentation (M = 18.39, SD = 10. 714); t (29) = .210, p = .835.  There was no 
significant difference in AA2 utilization or documentation (M = 17.60, SD = 13.954) and 
no AA2 utilization or documentation (M = 18.38, SD = 10,679); t (29) = .172, p = .864. 
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The results of the study indicated no significant relationship between 
pharmacological management and readmission.  This may be due in part to the limited 
amount of data for analysis.  The results suggested a potential difference in readmission 
with the utilization of ACEI or BB, but that impact can only be determined by an analysis 
of more data.  The results are presented in Tables 8 and 9.  The standard abbreviation for 
each pharmacological class is used to represent the utilization of that pharmacological 
class at the index admission/discharge.  This is followed by the standard abbreviation 
with the number 2 to represent utilization of that pharmacological class at readmission  
Table 8  
Multiple T-Test Results 
 N Mean (SD) number of days between 
discharge and readmission (time) 
ACEI         Non-adherent 18 17.56 (13.05) 
Adherent 13 18.92 (9.69) 
 
ACEI2       Non-adherent 23 17.13 (11.72) 
Adherent 8 21.00 (11.51) 
 
BB             Non-adherent 5 13.00 (9.93) 
adherent 26 19.12 (11.81) 
 
BB2           Non-adherent 5 13.00 (9.93) 
Adherent 26 19.12 (11.81) 
 
ARB          Non-adherent 21 18.76 (12.30) 
Adherent 10 16.80 (10.47) 
 
ARB2        Non-adherent 24 19.25 (11.44) 
Adherent 7 14.29 (12.22) 
 
AA             Non-adherent 23 18.39 (10.71) 
Adherent 8 17.38 (14.67) 
 
AA2           Non-adherent 21 18.38 (10.68) 
Adherent 10 1.  (13.95) 
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Table 9   
Multiple Independent T-Test Results 
 
Summary 
This chapter presented the results of the data analysis.  Data results revealed that 
the majority of these patients had more than one comorbid condition, along with their 
Variables Groups (n) Mean (SD) 
number of days 
between 
discharge and 
readmission 
(time) 
Test 
Statistic 
(p-value) 
95% C.I. 
    LL UL 
ACEI Non-adherent  (18) 
Adherent         (13) 
 
17.56 (13.05) 
18.92 (9.69) 
-0.319 
(0.752) 
 
-10.316 7.401 
ACEI2 Non-adherent  (23) 
Adherent          (8) 
 
17.13 (11.72) 
21.00 (11.51) 
-0.808 
(0.426) 
 
-13.665 5.926 
BB Non-adherent   (5) 
Adherent         (26) 
 
13.00 (9.93) 
19.12 (11.81) 
-1.083 
(0.288) 
 
-17.669 5.438 
BB2 Non-adherent   (5) 
Adherent         (26) 
 
13.00 (9.93) 
19.12 (11.81) 
-1.083 
(0.288) 
 
-17.669 5.438 
ARB  Non-adherent  (21) 
Adherent         (10) 
 
18.76 (12.30) 
16.80 (10.47) 
0.434 
(0.667) 
 
-7.280 11.204 
ARB2 Non-adherent  (24) 
Adherent          (7) 
 
19.25 (11.44) 
14.29 (12.22) 
0.996 
(0.327) 
 
-5.229 15.158 
AA Non-adherent (23) 
Adherent         (8) 
 
18.39 (10.71) 
17.38 (14.67) 
0.210 
(0.835) 
 
-8.882 10.914 
AA2 Non-adherent (21) 
Adherent        (10) 
18.38 (10.68) 
17.60 (13.95) 
0.172 
(0.864) 
 
-8.486 10.048 
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primary diagnosis of heart failure.  The data results did show that patients frequently 
readmit to the hospital within 30 days of discharge; however, the results did not illustrate 
a significant relationship between evidence-based pharmacological therapy and 
readmission.  This may be due to the lack of data.  Beta blockers were the most 
commonly used medication upon admission/discharge and readmission/discharge.  The 
results also showed that some of the pharmacological classes of medications were not 
utilized, or there was not sufficient documentation explaining why they were not being 
used.  The next chapter will discuss the conclusions and findings of this study, 
limitations, and recommendations for future research. 
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CHAPTER V – CONCLUSIONS, FINDINGS, AND RECOMMENDATIONS  
FOR FUTURE RESEARCH 
Introduction 
The purpose of this study was to explore the adherence to evidence-based 
guidelines for pharmacologic management by select Mississippi hospitals and their 
hospital readmission rates.  This was examined by determining to what extent select 
Mississippi hospitals adhere to evidence-based pharmacological management guidelines 
for the management of heart failure and by determining the relationship between 
adherence to guidelines for pharmacologic management of heart failure and readmission 
to hospital for select Mississippi hospitals.  Chapter V will highlight the study’s 
conclusions, findings, limitations, and recommendations for future research on this topic. 
Conclusion 
The researcher can conclude that the study successfully answered question one; 
however, question two would require additional data for analysis to determine if there is 
indeed a significance. 
Findings 
The overall findings of this study indicated there was no relationship between 
adherence to evidence-based guidelines for pharmacologic management and 
readmissions.  The first question addressed was: “To what extent are select Mississippi 
hospitals adhering to evidence-based pharmacological management guidelines for 
management of heart failure?”  Data was collected on a total of 31 patients.  The 
researcher searched the charts to examine the frequency of utilization of the four main 
pharmacological classes upon admission or discharge.  If the medication was not utilized, 
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the researcher went to the next step of searching for specific documentation 
contraindicating the use of the medication in the patients’ pharmacologic management.  
A frequency analysis was used to statistically analyze the extent to which 
evidence-based guidelines were being adhered to.  The results indicated that evidence-
based pharmacological medications were either not frequently prescribed or did not have 
sufficient documentation supporting or contraindicating the utilization of the medication 
in the patients’ pharmacological management.  BBs were the only medications identified 
as being prescribed frequently.  
The second research question addressed was: “What is the relationship between 
adherence to guidelines for pharmacologic management of heart failure and readmission 
to hospital for select Mississippi hospitals?”  First, a t-test was performed to analyze if 
there was a difference in the mean number of days between adherence and non-adherence 
of the four pharmacological classes.  The results of this test allowed the researcher to 
determine whether the adherence or non-adherence to each pharmacological class 
contributed to an increase or decrease in the mean number of days the patients stayed out 
of the hospital since discharge.  An increase in mean number of days in the non-adherent 
group would indicate not adhering to the pharmacological class was associated keeping 
patients out of the hospital longer.  A decrease in mean number of days in the non-
adherent group would indicate not adhering to the pharmacological class was not 
associated with keeping patients out of the hospital longer. 
A similar rationale was applied to the relationship between adherence of 
pharmacological classes and time.  An increase in mean number of days in the adherent 
group would indicate adhering to the pharmacological class was associated with keeping 
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patients out of the hospital longer.  A decrease in mean number of days in the adherent 
group would indicate adhering to the pharmacological class was not associated with 
keeping patients out of the hospital longer.  
According to the results of the t-tests, there was not significant difference in time 
among the pharmacological classes. For example, the patients in the ACEI non-adherent 
group stayed out of the hospital 17 days before being readmitted.  There was not a major 
difference in the ACEI adherent group because the patients in that group stayed out of the 
hospital only 18 days before being readmitted.  Similar results were seen among the other 
pharmacological classes.  These results indicated to the researcher there was not a 
relationship between adhering to the pharmacological classes and readmission. 
An independent samples t-test was then used to statistically analyze the 
relationship between adherence to guidelines for pharmacological management and 
readmission.  The results of the study indicated there was not a significant relationship 
between pharmacological management and readmission.  This may be due in part to the 
limited amount of data for analysis.   
Recommendations for Future Research 
The utilization of evidence-based interventions is an essential part of quality 
patient care.  Future research of this topic should include a larger sample to determine 
whether there is any significance between the utilization of evidence-based 
pharmacologic medications and readmissions.  This study was limited to a total of 31 
charts, which was due to chart availability and the limited number of staff available to 
pull more charts. Future studies should also include the incorporation of the patients’ 
comorbid conditions because they also have a significant influence on patient care and 
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their regimen of medications.  Yancy et al. (2013) made reference to the inclusion of 
comorbid conditions in future studies in their research gaps and recommendations for 
future research.  Several of the studies the authors reviewed excluded patients with 
conditions limiting their recommendations for these patients (p. e299).   
Qualitative studies on this topic would also prove beneficial.  Qualitative studies 
would offer insight from the patients’ perspectives on what influences their decision to 
readmit to the hospital and whether their compliance to their medication regimen 
influences readmission.  Qualitative studies would also offer information on whether 
patients have a thorough understanding of their disease and the necessary steps to 
effectively manage it. 
Another recommendation would be to use the data collected from this study as a 
measure of quality assurance in the healthcare facility.  This study can be utilized by the 
staff of the healthcare facility in which the data was collected to measure and improve 
quality care in the healthcare facility.  The data collected from this study could be used 
specifically as a learning tool to guide healthcare staff about the importance of evidence-
based practice and the basis of incorporating evidence-based practice into patient care.   
There are also implications for nurses and physicians.  While conducting the chart 
reviews, it was noted that there was not sufficient documentation contraindicating the 
utilization of evidence-based medications in the patient’s care.  Healthcare personnel are 
aware of the importance of documentation; however, sometimes it is important to remind 
them of the necessity of sufficient documentation.  Documentation is an essential part of 
continuity of care and can also be the difference between saving a person’s life.  All 
healthcare members involved in patient care refer to documentation many times before 
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decisions are made.  Nurses are especially aware of the importance of documentation 
because they are often taught that if a situation is not documented, then that situation did 
not occur.  Thus, sufficient documentation can be the turning point in legal cases 
concerning patient care.  
Summary 
This study explored the adherence to evidence-based guidelines for 
pharmacologic management by select Mississippi hospitals and the potential impact it 
had on their hospital readmission rates.  This was achieved by first determining to what 
extent a select Mississippi hospital adhered to evidence-based pharmacological 
management guidelines for the management of heart failure and second by determining 
the impact adherence to those guidelines had on readmission rates.  The results of the 
study did show a potential impact between adherence to guidelines and readmission rates; 
however, the results were limited to a potential impact due to the limited amount of data 
available for data analysis.  The study did, however, demonstrate the importance of 
incorporating evidence-based guidelines into the care patients receive and the importance 
of thorough documentation. 
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APPENDIX A – Data Abstraction Tool 
Date Data Collected _____________ 
 
Date Data Entered _____________ 
TITLE 
KERI A. BARRON, MSN, RN 
DATA COLLECTION FORM 
 
1.  Subject ID Number                 __________________ 
 
2.  Subject medical record number     __________________ 
 
DEMOGRAPHIC DATA 
3.  Age:  ________ 
4.  Gender:    
  
 Female       __________________
   
  
 Male        __________________ 
 
5.  Race/Ethnicity 
 Caucasian/White      __________________ 
 African American/Black     __________________ 
 Hispanic/Latino      __________________ 
 Asian American/Pacific Islander    __________________ 
 American Indian      __________________ 
CLINICAL DATA 
6.  Admission date       __________________ 
7.  Discharge date       __________________ 
8.  ICD-9 Code       __________________ 
9.  Stage of Heart Failure  
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 A        __________________ 
 B        __________________ 
 C        __________________ 
 D        __________________ 
10.  Height        __________________ 
11.  Weight        __________________ 
 
12.  Comorbid Conditions: 
 Diabetes       __________________ 
 Hypertension       __________________ 
 Ischemic Heart Disease     __________________ 
 Hyperlipidemia      __________________ 
 Anemia       __________________ 
 Chronic Kidney Disease     __________________ 
 COPD        __________________ 
 Atrial Fibrillation      __________________ 
 Myocardial Infarction      __________________ 
13.  Laboratory Values – Obtained at Admission 
 Blood Urea Nitrogen (BUN) (10-20)    __________________ 
 Creatinine (0.7-1.3)      __________________ 
 Brain Natriuretic Peptide (BNP) (    __________________ 
 Potassium (3.5 – 5.0)      __________________ 
 HgA1c (if diabetic) (3.9 – 6.9)    __________________ 
 Hemoglobin (13.5 – 17.5)     __________________ 
 61 
14.  Vital Signs at Admission   
 BP        __________________ 
 P        __________________ 
15.  Vital Signs at Discharge       
 BP        __________________ 
 P        __________________ 
16.  Smoking Status 
 Never Smoked                 __________________ 
 Current Smoker                 __________________ 
 Past Smoker                             __________________ 
17.  Pharmacological Heart Failure Treatment on Admission/Discharge 
 Angiotensin-converting enzyme inhibitors (Yes or No) __________________ 
  If no, documentation of reason why 
  ____________________________________________________________ 
  ____________________________________________________________ 
  ____________________________________________________________ 
 Beta blockers (Yes or No)                                                __________________ 
  If no, documentation of reason why 
  ____________________________________________________________ 
  ____________________________________________________________ 
  ____________________________________________________________ 
 Angiotensin receptor blockers (Yes or No)                           __________________ 
  If no, documentation of reason why 
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  ____________________________________________________________ 
  ____________________________________________________________ 
  ____________________________________________________________ 
 Aldosterone receptor antagonist (Yes or No)              __________________ 
  If no, documentation of reason why 
  ____________________________________________________________ 
  ____________________________________________________________ 
  ____________________________________________________________ 
18.  Pharmacological Heart Failure Treatment on Readmission  
 Readmission date       __________________ 
 Angiotensin-converting enzyme inhibitors (Yes or No) __________________ 
  If no, documentation of reason why 
  ____________________________________________________________ 
  ____________________________________________________________ 
  ____________________________________________________________ 
 Beta blockers (Yes or No)                                                     __________________ 
  If no, documentation of reason why 
  ____________________________________________________________ 
  ____________________________________________________________ 
  ____________________________________________________________ 
 Angiotensin receptor blockers (Yes or No)                           __________________ 
  If no, documentation of reason why 
  ____________________________________________________________ 
 63 
  ____________________________________________________________ 
  ____________________________________________________________ 
 Aldosterone receptor antagonist (Yes or No)              __________________ 
  If no, documentation of reason why 
  ____________________________________________________________ 
  ____________________________________________________________ 
  ____________________________________________________________ 
19.  Insurance Provider 
 Medicare       __________________ 
 Medicaid       __________________ 
 Medicare/Medicaid      __________________ 
 Private Insurance       __________________ 
 Non – Insured       __________________ 
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